. | pSS (n = 17) . | HC(n = 16) . | P-value . |
---|---|---|---|
Age, mean (s.d.) | 49.23 (14.37) | 44.38 (8.27) | 0.531 |
Female, n (%) | 16 (94.12) | 15 (93.75) | 0.965 |
Autoantibodies, n (%) | |||
ANA positive | 16 (94.12) | – | – |
Anti-SSA positive | 16 (94.12) | – | – |
Anti-SSB positive | 12 (70.59) | – | – |
Anti-Ro-52 positive | 16 (94.12) | – | – |
. | pSS (n = 17) . | HC(n = 16) . | P-value . |
---|---|---|---|
Age, mean (s.d.) | 49.23 (14.37) | 44.38 (8.27) | 0.531 |
Female, n (%) | 16 (94.12) | 15 (93.75) | 0.965 |
Autoantibodies, n (%) | |||
ANA positive | 16 (94.12) | – | – |
Anti-SSA positive | 16 (94.12) | – | – |
Anti-SSB positive | 12 (70.59) | – | – |
Anti-Ro-52 positive | 16 (94.12) | – | – |
Data are expressed as n (%) or mean (s.d.). ANA: anti-nuclear antibodies; anti-SSA: anti-Ro/SSA antibodies; anti-SSB: anti- La/SSB antibodies; anti-Ro-52: anti-Ro-52 antibodies.
. | pSS (n = 17) . | HC(n = 16) . | P-value . |
---|---|---|---|
Age, mean (s.d.) | 49.23 (14.37) | 44.38 (8.27) | 0.531 |
Female, n (%) | 16 (94.12) | 15 (93.75) | 0.965 |
Autoantibodies, n (%) | |||
ANA positive | 16 (94.12) | – | – |
Anti-SSA positive | 16 (94.12) | – | – |
Anti-SSB positive | 12 (70.59) | – | – |
Anti-Ro-52 positive | 16 (94.12) | – | – |
. | pSS (n = 17) . | HC(n = 16) . | P-value . |
---|---|---|---|
Age, mean (s.d.) | 49.23 (14.37) | 44.38 (8.27) | 0.531 |
Female, n (%) | 16 (94.12) | 15 (93.75) | 0.965 |
Autoantibodies, n (%) | |||
ANA positive | 16 (94.12) | – | – |
Anti-SSA positive | 16 (94.12) | – | – |
Anti-SSB positive | 12 (70.59) | – | – |
Anti-Ro-52 positive | 16 (94.12) | – | – |
Data are expressed as n (%) or mean (s.d.). ANA: anti-nuclear antibodies; anti-SSA: anti-Ro/SSA antibodies; anti-SSB: anti- La/SSB antibodies; anti-Ro-52: anti-Ro-52 antibodies.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.